Premium
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder‐relapser hepatitis C patients: a prospective multicentre randomized controlled study
Author(s) -
Portal I.,
Bourlière M.,
Halfon P.,
De Lédinghen V.,
Couzigou P.,
Bernard P. H.,
Blanc F.,
CaroliBosc F.,
Arpurt J. P.,
Vetter D.,
MathieuChandelier C.,
Chazouillères O.,
Thiefin G.,
Pol S.,
Sogni P.,
Abergel A.,
Bailly F.,
Picon M.,
Debonne J. M.,
Zamora C.,
Alleman I.,
Moreau X.,
Doll F.,
Eugène C.,
Ducloux S.,
Larrey D.,
Ouzan D.,
Grimaud J. C.,
Gouvernet J.,
Botti G.,
Gérolami V.,
Khiri H.,
Gérolami A.,
Gauthier A. P.,
BottaFridlund D.
Publication year - 2003
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.2003.00426.x
Subject(s) - ribavirin , medicine , regimen , gastroenterology , viral load , interferon , hepatitis c , alpha interferon , chronic hepatitis , immunology , human immunodeficiency virus (hiv) , virus
Summary. Low pretreatment viral load has consistently been shown to be an independent predictor of sustained response (SR) in patients with chronic hepatitis C infection. We assessed the efficacy of interferon (IFN) plus ribavirin vs IFN alone in low viraemic patients (<2 millions copies/mL) who had relapsed to a previous course of IFN and the efficacy of 24 vs 48 week combination therapy in high viraemic patients. Two hundred and ninety‐seven patients were randomly assigned to one of the four regimens after stratification on pretreatment viral load. All patients received IFN‐ α 2b (6 million units thrice weekly for 24 weeks and 3 million units thrice weekly for 24 weeks). Patients with low viraemia received either IFN‐ α 2b alone for 48 weeks (R1: 42 patients) or IFN‐ α 2b plus ribavirin (600 mg/day) for 24 weeks and IFN‐ α 2b alone for the next 24 weeks (R2: 48 patients). Patients with high viral load received either IFN‐ α 2b plus ribavirin for 24 weeks and then IFN‐ α 2b alone for the next 24 weeks (R3: 104 patients) or IFN‐ α 2b plus ribavirin for 48 weeks (R4: 103 patients). In low viraemic patients the rate of SR was 37.7% in group R1 and 59.6% in group R2 ( P < 0.05). In high viraemic patients, the rate of SR was 44.7% in group R3 and 51.4% in group R4 ( P : NS). Thirty‐one patients discontinued treatment (10.4%) without difference regarding treatment regimen. In the regimen using ribavirin we found no difference in terms of SR between patients receiving a dose of ribavirin below 10.6 mg/kg/day (55%) or over 10.6 mg/kg/day (58%). Histological improvement occurred in 70.2% of patients regardless of the regimen. Logistic regression showed that genotype 2 and 3, Knodell score <6 and alanine aminotransferase pretreatment level >3 × upper limit of normal were significantly and independently correlated with SR. In low viraemic patients who relapsed to a previous IFN treatment, combination therapy using high‐dose IFN and low‐dose ribavirin is better than high‐dose IFN alone. In high viraemic patients there was no benefit in increasing the duration of combination therapy from 24 to 48 weeks. In this study, it was found that low dose of ribavirin can be used safely and there is no effect of ribavirin dose on SR.